Breaking News Instant updates and real-time market news.

NVS

Novartis

, JNJ

Johnson & Johnson

09:22
07/18/17
07/18
09:22
07/18/17
09:22

On The Fly: Pre-market Movers

UP AFTER EARNINGS: Novartis (NVS), up 2%... Johnson & Johnson (JNJ), up marginally... UnitedHealth (UNH), up fractionally. ALSO HIGHER: Nektar Therapeutics (NKTR), up 4.5% after reporting data on a study of abuse potential of NKTR-181... Puma Biotechnology (PBYI), up 8.7% after the FDA grants approval of Nerlynx. DOWN AFTER EARNINGS: Ericsson (ERIC), down 13.2%... Bank of America (BAC), down marginally... Harley-Davidson (HOG), down 9.4%. ALSO LOWER: AMD (AMD), down 4.2% after being downgraded to Underweight from Equal Weight at Barclays.

NVS

Novartis

JNJ

Johnson & Johnson

UNH

UnitedHealth

NKTR

Nektar

$20.66

-0.01 (-0.05%)

PBYI

Puma Biotechnology

$86.10

-3.45 (-3.85%)

ERIC

Ericsson

$7.28

-0.15 (-2.02%)

BAC

Bank of America

HOG

Harley-Davidson

AMD

AMD

$13.80

-0.12 (-0.86%)

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 21

    Jul

  • 25

    Jul

  • 09

    Aug

  • 15

    Aug

  • 29

    Aug

  • 02

    Oct

NVS Novartis

07/18/17
WELS
07/18/17
NO CHANGE
WELS
Market Perform
Novartis report has cautious read-through for Mylan, Teva, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis' (NVS) Sandoz unit is one of the world's largest generic drug makers and he believes the proper read-through from its report is that the U.S. generic market remains challenging and that investors should remain cautious on the generics space. Maris, who said he would not be surprised to see Mylan (MYL) or Teva (TEVA) weaker following Novartis' report, keeps Market Perform ratings on those two names.
07/14/17
LEER
07/14/17
NO CHANGE
Target $36
LEER
Outperform
Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial
Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.
07/13/17
SBSH
07/13/17
NO CHANGE
SBSH
Novartis vote bodes well for Kite and Juno, says at Citi
Citi analyst Robyn Karnauskas believes the FDA's unanimous vote in favor of Novartis' (NVS) CAR-T bodes well for Kite Pharma (KITE) and Juno Therapeutics (JUNO). Yesterday's panel meeting provides a preview of what Kite can expect ahead of its November 29 FDA action date, Karnauskas tells investors in a research note. She believes the expert commentary from the panel has "overarching implications" for Kite and Juno, both of which are developing CAR-T therapies for multiple indications.
07/12/17
RHCO
07/12/17
NO CHANGE
Target $108
RHCO
Buy
bluebird bio recent weakness unwarranted, says SunTrust
SunTrust analyst Edward Nash views the weakness in bluebird bio (BLUE) shares since the FDA briefing document on Novartis' (NVSR) CAR T product candidate as unwarranted. The tone of the briefing document is neutral and emphasizes short-term toxicities observed in Novartis' studies and long-term safety concerns so that the Advisory Committee will be able to conduct a thorough discussion to determine the risk/benefit ratio, Nash tells investors in a research note. Further, he believes the data from Novartis and bluebird are not an apples-to-apples comparison and reminds investors of the "differentiated safety profile" that bluebird's bb2121 has demonstrated to date. He recommends buying bluebird on the recent selloff and reiterates a Buy rating on the name with a $108 price target.
JNJ Johnson & Johnson

06/14/17
RHCO
06/14/17
NO CHANGE
RHCO
Eli Lilly has positive read through from J&J data, says SunTrust
SunTrust analyst John Boris says that data for Johnson & Johnson's (JNJ) Invokana for diabetes represented a best-case scenario for Eli Lilly (LLY). J&J's drug "significantly reduced the combined risk of cardiovascular death, myocardial infarction and nonfatal stroke in diabetes patients at risk for or with a history of CV diseases," and its efficacy on CV death is positive for the SGLT-2 class, to which Eli Lilly's Jardiance also belongs, according to the analyst. But the data leaves Jardiance, which reduced CV death by a statistically significant 38% versus Invokana's non-significant 13%, as the best in the class, wrote the analyst, who reiterates a $101 price target and a Buy rating on Eli Lilly.
07/14/17
WELS
07/14/17
NO CHANGE
WELS
Underperform
J&J approval another negative for Valeant, says Wells Fargo
Wells Fargo analyst David Maris says Valeant Pharmaceuticals (VRX) has a new competitor in the psoriasis space after the FDA yesterday approved Tremfya from Johnson & Johnson (JNJ). The news is another negative for Valeant, which is about to launch its own psoriasis treatment, Siliq, in the second half of 2017, Maris tells investors in a research note. With Talz from Eli Lilly (LLY), Humira from AbbVie (ABBV), Cosentyx from Novartis (NVS) and now J&J as a new competitor, Valeant is unlikely to be competitive in the psoriasis market, Maris contends. He believes his peak sales estimate of $250M for Siliq may prove optimistic given the competition. Maris an Underperform rating on Valeant with a $9 price target. The drugmaker closed yesterday at $17.29.
06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/20/17
ADAM
06/20/17
NO CHANGE
Target $10
ADAM
Buy
Novadaq competing bids possible if not probable, says Canaccord
Canaccord analyst Jason Mills noted Novadaq (NVDQ) received an acquisition offer from Stryker (SYK) at a much greater equity value than what the company was trading at prior to the bid. Although he thinks Stryker is the most logical buyer of the franchise, he thinks there are several other potential acquirers, including Medtronic (MDT), Johnson & Johnson (JNJ) and Intuitive Surgical (ISRG), in that order. Mills believes this is a good exit for the company and that Stryker is getting a good asset. Mills maintains his Buy rating and $10 price target on Novadaq shares.
UNH UnitedHealth

06/23/17
JEFF
06/23/17
NO CHANGE
JEFF
Jefferies says healthcare rally 'appropriate' after 'toothless' AHCA rewrite
Jefferies analyst David Windley said the rally yesterday in healthcare stocks was appropriate given the "anemic" rewrite of the AHCA healthcare bill by Senate Republicans. The key changes are removal of "pay-for" taxes, a somewhat longer runway for Exchange cost-sharing reduction subsidies, and delayed Medicaid transition to per capita caps, he tells investors. Windley called Cigna (CI) "probably the safest MCO in this noise", adding that Humana (HUM) would benefit most from the proposed removal of the health insurer fee. Other publicly traded healthcare insurers include Aetna (AET), Anthem (ANTM), Centene (CNC), Health Net (HNT), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
06/23/17
LEER
06/23/17
NO CHANGE
LEER
Outperform
Draft version of Senate healthcare bill better than expected, says Leerink
Leerink analyst Ana Gupte said she views the draft version of the Senate healthcare bill as better than expected, stating that stabilization of the Exchanges and risk stabilization is a direct positive for health insurers and indirect positive for facility operators. The Senate bill maintains the House bill's plan to repeal all "ObamaCare" industry fees and taxes, which is a positive for Managed Care and Medical Technology players, Gupte adds. She keeps Outperform ratings on Anthem (ANTM), UnitedHealth (UNH), Cigna (CI), Humana (HUM), WellCare (WCG), Molina Healthcare (MOH) and acute care hospital operators HCA Holdings (HCA), Tenet (THC) and LifePoint (LPNT).
06/27/17
KEYB
06/27/17
DOWNGRADE
KEYB
Sector Weight
LabCorp downgraded on potential acquisition at KeyBanc
As noted earlier, KeyBanc downgraded LabCorp to Sector Weight from Overweight. Analyst Donald Hooker downgraded the stock based on his belief that the company implied that it may make an "expensive" deal to acquire a contract research organization. The analyst adds that the upcoming renewal of the company's contract with UnitedHealth (UNH) in 2H18 creates uncertainty.He expects to hear news about the deal "in coming months."
07/13/17
FBCO
07/13/17
NO CHANGE
Target $200
FBCO
Outperform
UnitedHealth price target raised to $200 from $195 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for UnitedHealth to $200 from $195 ahead of Q2 results. He reiterates an Outperform rating on the shares.
NKTR Nektar
$20.66

-0.01 (-0.05%)

06/05/17
ROTH
06/05/17
NO CHANGE
Target $31
ROTH
Buy
Nektar NKTR-214 efficacy, safety signals encouraging, says Roth Capital
Roth Capital analyst Michael Higgins said Nektar's update at ASCO on NKTR-214, its Phase 2-ready IO candidate, included encouraging efficacy and safety and tolerability signals. He keeps a Buy rating and $31 price target on Nektar shares.
05/30/17
ROTH
05/30/17
NO CHANGE
Target $31
ROTH
Buy
Gottlieb remarks suggest more leeway for Nektar drug approval, says Roth Capital
Roth Capital analyst Michael Higgins noted that the first FDA Voice Blog issued by new commissioner Scott Gottlieb was dedicated to the ongoing opioid abuse crisis and he believes Gottlieb is directing the FDA to be more aggressive and take every opportunity to try to reduce prescription opioid and heroin abuse. Prior to Gottlieb's blog, Higgins had expected Nektar would need to run another Phase 3 trial before the NKTR-181 NDA could be filed; after it he now believes NKTR-181's NDA will not require another such trial. The analyst has a Buy rating and $31 price target on Nektar shares.
03/21/17
JPMS
03/21/17
NO CHANGE
Target $24
JPMS
Overweight
Nektar price target raised to $24 from $18 at JPMorgan
JPMorgan analyst Jessica Fye raised her price target for Nektar Therapeutics to $24 citing the positive phase III results for NKTR-181 in pain. The analyst sees a "strong probability" that Nektar partners the drug through the rest of phase III development and to commercialization. She keeps an Overweight rating on the shares.
03/21/17
JEFF
03/21/17
NO CHANGE
Target $25
JEFF
Buy
Nektar price target raised to $25 from $17 at Jefferies
Jefferies analyst David Steinberg raised his price target for Nektar Therapeutics to $25 citing the "unexpected" Phase 3 success for NKTR-181. In a research note tiled "NKTR-181 Back From the Dead; Could Become a Major Product in Chronic Pain," Steinberg says the drug could become the company's largest and most profitable product since it directly addresses the "opioid epidemic." NKTR-181 could bring "significant value" to Nektar as early as 2020, the analyst contends. Steinberg adds that the company now fits his takeover thesis. He keeps a Buy rating on the shares.
PBYI Puma Biotechnology
$86.10

-3.45 (-3.85%)

07/18/17
JPMS
07/18/17
NO CHANGE
JPMS
Overweight
Puma's label for Nerlynx a best case outcome, says JPMorgan
JPMorgan analyst Cory Kasimov views the label for Puma Biotechnology's breast cancer drug Nerlynx as a best case outcome. The label does not limit the patient population to HR+, as many investors expected, and does not include a boxed warning as diarrhea is in the warnings and precautions section, Kasimov tells investors in a research note. The analyst sees room for the shares to move "materially higher" given the "scarcity value of an approved and unencumbered" oncology asset as well as the 20% short interest in the name. He reiterates an Overweight rating on Puma Biotechnology.
07/18/17
SBSH
07/18/17
NO CHANGE
Target $114
SBSH
Buy
Citi ups Puma target to $114 following FDA approval of Nerlynx
Citi analyst Yigal Nochomovitz raised his price target for Puma Biotechnology to $114 from $105 after the FDA approved the company's breast cancer drug Nerlynx. The label is broad and the required two cycles of prophylaxis is "fully within expectations," Nochomovitz tells investors in a research note. He notes that his takeout scenario moves to $143 per share from $136. The analyst keeps a Buy rating on Puma shares. The stock traded up 7% to $92.50 last night in the after-hours.
07/18/17
FBCO
07/18/17
NO CHANGE
Target $118
FBCO
Outperform
Puma Biotechnology price target raised to $118 from $90 at Credit Suisse
Credit Suisse analyst Alethia Young raised her price target for Puma Biotechnology to $118 from $90, saying she is moving her base case to an M&A DCF because she thinks that this remains the likely outcome from here. The analyst reiterates an Outperform rating on the shares.
07/18/17
STFL
07/18/17
NO CHANGE
STFL
Puma Biotechnology price target raised to $118 from $105 at Stifel
Stifel analyst Thomas Shrader raised his price target on Puma after the company announced that its neratinib drug for breast cancer had been approved. The analyst says the company now probably has to decide whether to build a sales force or sell itself. He thinks that the drug's "surprisingly broad label" has made the company more attractive to potential acquirers. Shrader keeps a Buy rating on the shares.
ERIC Ericsson
$7.28

-0.15 (-2.02%)

06/08/17
SBSH
06/08/17
INITIATION
SBSH
Buy
Ericsson initiated with a Buy at Citi
Citi analyst Amit Harchandani started Ericsson with a Buy rating and SEK 75 price target. The analyst sees improved execution supporting a company turnaround.
06/14/17
SOCG
06/14/17
INITIATION
SOCG
Hold
Ericsson initiated with a Hold at Societe Generale
06/02/17
06/02/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Synergy Pharmaceuticals (SGYP) initiated with an Overweight at Cantor. 2. Fastenal (FAST) was initiated with an Overweight at Stephens and a Neutral at JPMorgan. 3. Ericsson (ERIC) was reinstated with a Buy at BofA/Merrill while Nokia (NOK) was reinstated with a Neutral. 4. John Bean Technologies (JBT) initiated with a Neutral at JPMorgan. 5. Biocept (BIOC) initiated with a Buy at Chardan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/02/17
BOFA
06/02/17
INITIATION
BOFA
Buy
Ericsson reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Tal Liani reinstated Ericsson with a Buy citing limited downside given valuation, market near trough levels, and margins.
BAC Bank of America

07/18/17
NOMU
07/18/17
NO CHANGE
Target $27
NOMU
Buy
Bank of America NII softness could weight on shares, says Nomura Instinet
Nomura Instinet analyst Steven Chubak said Bank of America reported a modest core beat but the NII miss and elevated bar for Q3 could result in modest share underperformance. The analyst remains encouraged by fee income resiliency, favorable credit trends, strong capital build, and compelling risk/reward, and reiterates his Buy rating and $27 price target.
04/24/17
04/24/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Disney (DIS) downgraded to Hold from Buy at Loop Capital with analyst David Miller citing valuation following the stock hitting a 52-week high on Friday. The strength in the stock over the last nine months has appropriately priced in the company's growth rate, said Miller, who maintains a $118 price target on Disney shares. 2. Groupon (GRPN) downgraded to Underweight on lackluster ad spend at Morgan Stanley with analyst Brian Nowak saying its recent local advertiser survey indicate lackluster forward advertiser spending and believes Groupon will need to spend more in order to grow North America Local Billings, which the Street seems to be underestimating. 3. Grainger (GWW) downgraded to Market Perform from Outperform at William Blair with analyst Ryan Merkel citing a lack of confidence in the company's repricing strategy. 4. Bank of America (BAC) downgraded to Hold from Buy at Berenberg with analyst James Chappell saying it is time to take profits. Interest rates unlikely to rise as much as has been priced into bank equity valuations, Chappell tells investors in a research note. Further, regulation and tax reform are likely to take longer than expected and not be as beneficial for the banks as many might have hoped, the analyst adds. He upped his price target for Bank of America shares to $22 from $15. 5. DuPont Fabros (DFT) downgraded to Hold from Buy at Stifel with analyst Matthew Heinz saying shares are fully valued and demand patterns have shifted. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/09/17
RBCM
06/09/17
NO CHANGE
RBCM
House financial reform bill unlikely to advance in Senate, says RBC Capital
RBC Capital analyst Gerard Cassidy says that the financial regulation reform bill passed yesterday by the House would help the banking sector but probably won;t be passed by the Senate. Large publicly traded banks include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
07/11/17
BARD
07/11/17
NO CHANGE
BARD
Big bank set-up not great, would sell into extended rally, says Baird
Baird analyst David George does not see a great set-up for money-center banks heading into Q2 earnings. He said the trade looks crowded and he would be a seller into an extended rally. George said the risk/reward is less attractive following the sector's most recent rally as economic growth remains muted and the pace of NIM expansion may slow. George believes the biggest potential catalyst would be a gradual steepening of the yield curve and pick-up on loan growth.
HOG Harley-Davidson

07/12/17
07/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Monsanto (MON) downgraded to Hold from Buy at Jefferies with analyst Laurence Alexander saying Bayer's (BAYRY) all-cash offer appears on track for year-end. The analyst views the deal failing as a "low-probability scenario" and keeps a $128 price target for the shares. 2. Freeport McMoRan (FCX) downgraded to Sell from Hold at Berenberg. 3. Kimberly-Clark (KMB) downgraded to Sell from Neutral at UBS with analyst Stephen Powers saying the stock's 11% rise year-to-date is not based on fundamentals but news flow of consolidation in the Household Products sector. 4. Harley-Davidson (HOG) downgraded to Market Perform from Outperform at Bernstein with analyst David Beckel citing his belief that "demographic shifts and a stagnating economy" will prevent demand for the company's motorcycles from growing in the U.S. for the next five years. 5. IMAX (IMAX) downgraded to Market Perform from Outperform at Barrington with analyst James Goss saying positive catalysts "might take some time to develop." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/13/17
RBCM
07/13/17
NO CHANGE
RBCM
Harley-Davidson acquisition of Ducati would be 'risky,' says RBC Capital
After Reuters reported that Harley-Davidson may look to buy Ducati, RBC Capital analyst Joseph Spak calls Ducati "a great brand," but says that acquiring it "could set up a culture clash" and would be "risky" for Harley-Davidson. After conducting checks with U.S. powersports dealers, Spak estimates that Harley's U.S. unit retail sales came in at -1% to +1% year-over-year. He continues to expect the sector to generate "stagnant growth over coming years" and keeps a Sector Perform rating on the name.
07/13/17
LBOW
07/13/17
NO CHANGE
LBOW
Harley-Davidson Q2 results likely to miss expectations, says Longbow
Longbow analyst David Macgregor expects Harley-Davidson's Q2 results to come in below expectations as he says his checks indicate that its U.S. retail sales fell 1%-3%. The analyst keeps a Neutral rating on the stock.
07/13/17
CLVD
07/13/17
NO CHANGE
CLVD
Neutral
Harley-Davidson checks point to sluggish demand, says Cleveland Research
Cleveland Research said its checks are pointing to sluggish demand for Harley-Davidson and the firm expects only a modest improvement in retail sales in Q2, which will likely be viewed by the market as a disappointment. The firm, which expects fiscal year shipments to miss the consensus view, keeps a Neutral rating on Harley shares.
AMD AMD
$13.80

-0.12 (-0.86%)

07/18/17
BMOC
07/18/17
NO CHANGE
BMOC
AMD outlook mixed, says BMO Capital
BMO Capital analyst Ambrish Srivastava says he is "a bit cautious" on AMD (AMD) heading into its results as he believes that crypto mining demand and profitability "could collapse." However, the analyst remains upbeat on AMDs longer term outlook, as he thinks that it can deliver "consistent execution in its emerging product areas" and gain share from Intel (INTC) and Nvidia (NVDA). He keeps an Outperform rating on AMD.
07/18/17
LEHM
07/18/17
UPGRADE
Target $60
LEHM
Equal Weight
Xilinx upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Blayne Curtis upgraded Xilinx (XLNX) to Equal Weight saying he sees more downside elsewhere in the U.S. Semiconductors space. The analyst raised his price target for the shares to $60 from $53. The analyst this morning downgraded both AMD (AMD) and Cirrus Logic (CRUS) to Underweight.
07/18/17
LEHM
07/18/17
DOWNGRADE
Target $9
LEHM
Underweight
AMD downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Blayne Curtis downgraded AMD (AMD) to Underweight with an unchanged price target of $9. The chipmaker closed yesterday down 12c to $13.80. The analyst is "unconvinced" that AMD products will gain enough traction to support the current valuation. He also has difficulty "getting anywhere near" the company's long-term earnings per share target of 75c. Curtis likes shares of Cavium (CAVM) and Cypress Semiconductor (CY) in the U.S. Semiconductors space heading into Q2 earnings.
07/10/17
JPMS
07/10/17
NO CHANGE
JPMS
JPMorgan raises semiconductor market forecasts after strong May
JPMorgan analyst Hisashi Moriyama attributes data center demand due to the spread of cloud computing and expanding applications for Internet of Things as driving better than expected May growth in the semiconductor market. The analyst, who also believes growth to the automobile market is accelerating, raised his semiconductor market forecasts given the strong May. Publicly traded companies in the semiconductor space include AMD (AMD), Intel (INTC), Marvell (MRVL), Microchip (MCHP), Micron (MU), Nvidia (NVDA), Qualcomm (QCOM) and Texas Instruments (TXN).

TODAY'S FREE FLY STORIES

03:25
07/25/17
07/25
03:25
07/25/17
03:25
General news
FX Action: USD-JPY dipped back to around the 111.00 level »

FX Action: USD-JPY dipped…

02:40
07/25/17
07/25
02:40
07/25/17
02:40
General news
FX Update: Narrow ranges have been the order of the day »

FX Update: Narrow ranges…

MMM

3M

$210.00

-1.16 (-0.55%)

, MCD

McDonald's

$151.85

-2.07 (-1.34%)

20:25
07/24/17
07/24
20:25
07/24/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MMM

3M

$210.00

-1.16 (-0.55%)

MCD

McDonald's

$151.85

-2.07 (-1.34%)

UTX

United Technologies

$123.13

-0.36 (-0.29%)

LLY

Eli Lilly

$84.74

0.08 (0.09%)

DD

DuPont

$84.35

-0.19 (-0.22%)

CAT

Caterpillar

$108.18

1.59 (1.49%)

BIIB

Biogen

$284.70

1.78 (0.63%)

GM

General Motors

$35.82

-0.25 (-0.69%)

KMB

Kimberly-Clark

$123.81

-1.47 (-1.17%)

HCA

HCA Holdings

$86.09

0.36 (0.42%)

PCAR

Paccar

$69.14

0.27 (0.39%)

TROW

T. Rowe Price

$81.10

0.27 (0.33%)

FCX

Freeport McMoRan

$12.96

-0.05 (-0.38%)

NEM

Newmont Mining

$33.90

-0.49 (-1.42%)

DGX

Quest Diagnostics

$109.44

0.05 (0.05%)

WAT

Waters

$185.01

-0.23 (-0.12%)

CNC

Centene

$84.20

-0.53 (-0.63%)

STX

Seagate

$39.76

0.18 (0.45%)

DPZ

Domino's Pizza

$213.97

0.75 (0.35%)

IPG

Interpublic Group

$25.57

0.06 (0.24%)

JBLU

JetBlue

$22.76

-0.69 (-2.94%)

LW

Lamb Weston

$44.75

-0.25 (-0.56%)

GPK

Graphic Packaging

$13.77

0.04 (0.29%)

AKS

AK Steel

$6.03

-0.17 (-2.74%)

SVU

Supervalu

$3.25

-0.01 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 30

    Jul

  • 01

    Aug

  • 02

    Aug

  • 02

    Aug

  • 10

    Aug

  • 15

    Aug

  • 23

    Aug

  • 11

    Sep

  • 11

    Sep

  • 15

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

QCOM

Qualcomm

$53.22

-0.62 (-1.15%)

, AAPL

Apple

$152.09

1.82 (1.21%)

19:16
07/24/17
07/24
19:16
07/24/17
19:16
Periodicals
Qualcomm claims tech group misdirects trade regulators, Reuters says »

Qualcomm (QCOM) has…

QCOM

Qualcomm

$53.22

-0.62 (-1.15%)

AAPL

Apple

$152.09

1.82 (1.21%)

GOOG

Alphabet

$980.34

7.42 (0.76%)

GOOGL

Alphabet Class A

$998.31

4.47 (0.45%)

AMZN

Amazon.com

$1,038.95

13.28 (1.29%)

MSFT

Microsoft

$73.60

-0.19 (-0.26%)

FB

Facebook

$166.00

1.57 (0.95%)

INTC

Intel

$34.50

-0.23 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 26

    Jul

  • 27

    Jul

  • 27

    Jul

  • 01

    Aug

  • 10

    Aug

  • 15

    Aug

  • 05

    Sep

  • 13

    Sep

SMBC

Southern Missouri Bancorp

$31.32

-0.38 (-1.20%)

18:53
07/24/17
07/24
18:53
07/24/17
18:53
Hot Stocks
Southern Missouri Bancorp increases dividend 10% to 11c »

Missouri Bancorp …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

VLKAY

Volkswagen

$32.19

-0.79 (-2.40%)

18:47
07/24/17
07/24
18:47
07/24/17
18:47
Periodicals
VW diesel car owners declining refit to lose registration, Reuters says »

Owners of Volkswagen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRCI

SRC Energy

$7.17

0.04 (0.56%)

18:43
07/24/17
07/24
18:43
07/24/17
18:43
Hot Stocks
SRC Energy says 36 gross wells seen adding to production in 2H »

SRC continues to execute…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Aug

BABA

Alibaba

$152.26

0.37 (0.24%)

18:42
07/24/17
07/24
18:42
07/24/17
18:42
Periodicals
Alibaba in talks to make major investment in Tokopedia, Bloomberg says »

Alibaba is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TM

Toyota

$109.41

0.1 (0.09%)

18:39
07/24/17
07/24
18:39
07/24/17
18:39
Periodicals
Toyota could sell new generation of EVs in Japan in 2022, Bloomberg says »

Toyota may sell the next…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CG

Carlyle Group

$20.25

-0.25 (-1.22%)

18:27
07/24/17
07/24
18:27
07/24/17
18:27
Periodicals
Carlyle seeks $15B for new U.S. buyout fund, Bloomberg reports »

Carlyle Group is seeking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDAIF

Daimler AG

$71.00

-1.9399 (-2.66%)

, TCEHY

Tencent

$38.98

0.785 (2.06%)

18:24
07/24/17
07/24
18:24
07/24/17
18:24
Periodicals
Daimler invests in Chinese self-driving startup Momenta, WSJ reports »

Daimler (DDAIF) is…

DDAIF

Daimler AG

$71.00

-1.9399 (-2.66%)

TCEHY

Tencent

$38.98

0.785 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRBA

First Bank

$12.30

0.05 (0.41%)

18:22
07/24/17
07/24
18:22
07/24/17
18:22
Earnings
First Bank reports Q2 EPS 15c, consensus 17c »

Reports Q2 revenue $9.1M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

PCH

Potlatch

$47.55

-0.55 (-1.14%)

18:22
07/24/17
07/24
18:22
07/24/17
18:22
Earnings
Potlatch reports Q2 EPS 59c, consensus 35c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

CAT

Caterpillar

$108.18

1.59 (1.49%)

18:17
07/24/17
07/24
18:17
07/24/17
18:17
Periodicals
Caterpillar poised to move higher, Barron's reports »

At approximately 20 times…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

HA

Hawaiian Holdings

$44.80

-0.5 (-1.10%)

, EADSY

Airbus

$20.89

-0.005 (-0.02%)

18:16
07/24/17
07/24
18:16
07/24/17
18:16
Hot Stocks
Hawaiian unveils three new west coast routes, begins sales for A321neo flights »

Hawaiian Airlines (HA)…

HA

Hawaiian Holdings

$44.80

-0.5 (-1.10%)

EADSY

Airbus

$20.89

-0.005 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

GS

Goldman Sachs

$218.18

-2 (-0.91%)

17:53
07/24/17
07/24
17:53
07/24/17
17:53
Periodicals
Goldman Sachs pulls back from ETF lead market making, Reuters reports »

Goldman Sachs is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 01

    Aug

  • 17

    Oct

IBM

IBM

$145.99

-1.09 (-0.74%)

17:48
07/24/17
07/24
17:48
07/24/17
17:48
Hot Stocks
IBM granted patent to protect cryptographic keys and codes »

IBM announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$980.34

7.42 (0.76%)

17:48
07/24/17
07/24
17:48
07/24/17
17:48
Hot Stocks
Breaking Hot Stocks news story on Alphabet »

Alphabet's Pichai…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

CWH

Camping World

$31.15

-0.7 (-2.20%)

17:46
07/24/17
07/24
17:46
07/24/17
17:46
Hot Stocks
Camping World acquires American RV in Gran Rapids, Michigan »

Camping World Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$980.34

7.42 (0.76%)

17:39
07/24/17
07/24
17:39
07/24/17
17:39
Hot Stocks
Breaking Hot Stocks news story on Alphabet »

Alphabet CEO says not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

GOOG

Alphabet

$980.34

7.42 (0.76%)

17:37
07/24/17
07/24
17:37
07/24/17
17:37
Hot Stocks
Breaking Hot Stocks news story on Alphabet »

Alphabet says seeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

DKL

Delek Logistics

$34.70

-0.3 (-0.86%)

17:33
07/24/17
07/24
17:33
07/24/17
17:33
Hot Stocks
Delek Logistics increases dividend 2.2c to 70.5c »

Delek Logistics Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

AIRT

Air T

$16.00

0.05 (0.31%)

17:32
07/24/17
07/24
17:32
07/24/17
17:32
Hot Stocks
Air T receives Nasdaq notice letter »

Air T announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFSC

Enterprise Financial

$40.70

0.45 (1.12%)

17:31
07/24/17
07/24
17:31
07/24/17
17:31
Earnings
Enterprise Financial reports Q2 core EPS 56c, consensus 62c »

Rreports Q2 return on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 01

    Aug

CLB

Core Laboratories

$106.30

0.61 (0.58%)

17:30
07/24/17
07/24
17:30
07/24/17
17:30
Hot Stocks
Breaking Hot Stocks news story on Core Laboratories »

Core Laboratories reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 29

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.